Trial Profile
Expanded Access Protocol; Intermediate Size Protocol: Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure Who Are Refractory to Standard Therapy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 23 May 2018
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Decompensated heart failure
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Tenax Therapeutics
- 10 May 2018 Status changed from recruiting to completed.
- 28 Nov 2016 New trial record